Crinetics Pharmaceuticals (CRNX) Non Operating Income (2017 - 2026)

Crinetics Pharmaceuticals' Non Operating Income history runs 10 years deep, the most recent figure standing at $12.5 million for Q1 2026.

• In Q1 2026, Non Operating Income rose 6273.89% year-over-year to $12.5 million; the TTM figure through Mar 2026 stood at $64.4 million (up 91.32% YoY), while the FY2025 annual figure was $51.6 million, up 26.19% from the prior year.
• Non Operating Income was $12.5 million for Q1 2026 at Crinetics Pharmaceuticals, down from $51.9 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $51.9 million in Q4 2025 to a low of -$203000.0 in Q1 2025.
• Historically, Non Operating Income has averaged $7.3 million across 5 years, with a median of $2.0 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Non Operating Income slumped 179.31% in 2022, then soared 20796.23% in 2024.
• A 5-year view of Non Operating Income shows it stood at $2.6 million in 2022, then soared by 425.38% to $13.5 million in 2023, then gained by 5.0% to $14.2 million in 2024, then soared by 266.53% to $51.9 million in 2025, then slumped by 75.83% to $12.5 million in 2026.
• The last three Non Operating Income figures came in at $12.5 million (Q1 2026), $51.9 million (Q4 2025), and -$49000.0 (Q3 2025), per Business Quant data.